<DOC>
	<DOCNO>NCT01516970</DOCNO>
	<brief_summary>The primary purpose study ass rate early discontinuation randomize Human Immunodeficiency Virus ( HIV ) Postexposure Prophylaxis ( PEP ) reason confirmation negative HIV infection status index person patient receive HIV PEP least 28 maximum 30 day .</brief_summary>
	<brief_title>Human Immunodeficiency Virus ( HIV ) Postexposure Prophylaxis ( PEP ) With Darunavir/Ritonavir ( DRV/r )</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( people involve know identity intervention ) , active-controlled ( patient assign either recognize effective treatment study medication ) , parallel-group ( treatment group treat time ) , multicenter study compare DRV/r PEP ( DRV/r administer 2 NRTIs select discretion investigator ) standard care PEP ( per German-Austrian guideline ) patient risk HIV infection due HIV exposure occupational injury non-occupational exposure . This study consist screen period , treatment period follow period . HIV PEP administer total least 28 day maximum 30 day treatment period , include prestudy HIV PEP initiate screen . Approximately 318 patient screen enrolled ensure least 131 patient randomly assign receive DRV/r PEP standard care PEP . Safety evaluate entire study period . Data relate patient 's functional impairment conjunction HIV PEP collect Day 1 baseline data , Days 14 28 well Month 3 .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Occupational injury nonoccupational exposure document human immunodeficiency virus ( HIV ) exposure , potential HIV exposure Indication HIV postexposure prophylaxis ( PEP ) , determine treat physician and/or investigator Women must : postmenopausal ( least 2 year ) , surgically sterile , use oral contraceptive Willing continue HIV PEP 28 day Positive HIV rapid test History liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastro intestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance Pregnant breastfeed Any condition , opinion investigator , would compromise wellbeing participant study prevent participant meeting perform study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Human Immunodeficiency Virus ( HIV ) Post exposure prophylaxis</keyword>
	<keyword>DRV/r</keyword>
	<keyword>Occupational injury</keyword>
	<keyword>Non-occupational exposure</keyword>
	<keyword>Prezista</keyword>
	<keyword>Darunavir/r</keyword>
</DOC>